Brokerages Expect China Biologic Products, Inc. (CBPO) to Announce $1.11 EPS

China Biologic Products, Inc. (NASDAQ:CBPO) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a one year consensus price target of $111.67 for the company and are anticipating that the company will post $1.11 EPS for the current quarter, according to Zacks. Zacks has also assigned China Biologic Products an industry rank of 111 out of 265 based on the ratings given to its competitors.

CBPO has been the topic of several recent research reports. BidaskClub cut shares of China Biologic Products from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Zacks Investment Research raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a research report on Wednesday, November 15th. Finally, Jefferies Group LLC reissued a “buy” rating on shares of China Biologic Products in a research report on Friday, August 4th.

WARNING: “Brokerages Expect China Biologic Products, Inc. (CBPO) to Announce $1.11 EPS” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/05/brokerages-expect-china-biologic-products-inc-cbpo-to-announce-1-11-eps.html.

Shares of China Biologic Products (NASDAQ:CBPO) opened at $86.07 on Monday. The stock has a market cap of $2,376.34, a price-to-earnings ratio of 19.17, a PEG ratio of 1.41 and a beta of 1.71. China Biologic Products has a 1-year low of $72.21 and a 1-year high of $122.19.

Hedge funds have recently added to or reduced their stakes in the stock. Jennison Associates LLC increased its stake in shares of China Biologic Products by 0.8% during the second quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock worth $653,000 after buying an additional 44 shares during the period. BlackRock Inc. increased its stake in China Biologic Products by 694.1% in the first quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock valued at $151,007,000 after purchasing an additional 1,318,183 shares during the last quarter. Geode Capital Management LLC increased its stake in China Biologic Products by 15.4% in the first quarter. Geode Capital Management LLC now owns 14,309 shares of the biopharmaceutical company’s stock valued at $1,432,000 after purchasing an additional 1,906 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in China Biologic Products by 9.5% in the first quarter. Goldman Sachs Group Inc. now owns 58,559 shares of the biopharmaceutical company’s stock valued at $5,863,000 after purchasing an additional 5,091 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in China Biologic Products by 67.3% in the first quarter. Bank of America Corp DE now owns 56,118 shares of the biopharmaceutical company’s stock valued at $5,619,000 after purchasing an additional 22,583 shares during the last quarter. Hedge funds and other institutional investors own 71.07% of the company’s stock.

About China Biologic Products

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply